|
Data Science and Analytics |
|
ISchool 296A Spring 2012 |
|
Data Science and Analytics in Cancer Pharmaceutics Dr. Paul Rejto Director, Pfizer Worldwide R&D Abstract A brief introduction to current challenges in cancer pharmaceutics will be followed by three applications of data mining from cancer research practice: 1) Next-generation sequencing to identify recurrent somatic variants in gastric cancer, 2) Mining protein databases for candidate oncogenes, 3) Predictive markers of response via preclinical profiling. The utility of computational algorithms will be emphasized and future opportunities highlighted.
Bio Dr. Rejto is Director of Computational Biology, Oncology Research, Pfizer Worldwide R&D. Paul trained in physical and theoretical chemistry (Harvard A.B. magna cum laude; Stanford Ph.D.; UC Berkeley post-doc) and joined Pfizer La Jolla (at the time Agouron Pharmaceuticals) in 1994. His research interests include computational methods to support target discovery and validation, animal models, patient selection, resistance modeling and combination therapy. During his career, Paul has developed and applied tools for structure-based drug design, led a team that progressed compounds for the treatment of diabetes into the clinic, and built the computational biology group at Pfizer La Jolla.
|
